Related Experiment Video
Updated: Jun 9, 2026

Determining the Phagocytic Activity of Clinical Antibody Samples
Published on: November 30, 2011
Why antibodies disobey the Hippocratic Oath and end up doing harm: a new clue
1Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, New York, New York 10461, USA. l.pirofski@einstein.yu.edu
Abstract:
The appearance of methicillin-resistant Staphylococcus aureus (MRSA) as an endemic microbe, first in hospital and health care settings and more recently in the community, has led to a disastrous situation in which use of the available antibiotic armamentarium is increasingly ineffective and spawns further antibiotic resistance. This vicious cycle highlights the pressing need for an S. aureus vaccine. However, to date, clinical trials with S. aureus vaccines have not demonstrated sustained efficacy. In this issue of the JCI, Skurnik and colleagues report that specific antibodies to two different S. aureus surface polysaccharides, which independently promote effector cell killing of S. aureus in vitro and protection against S. aureus in animal models, bind to and abrogate the activity of one another when they are combined. This fascinating finding suggests a new paradigm to explain the failure of antibody immunity to S. aureus.
Insights
Antibodies targeting Staphylococcus aureus surface polysaccharides show promise for vaccines. However, combining antibodies against two polysaccharides may hinder their effectiveness, suggesting a new challenge for S. aureus vaccine development.
Area of Science:
- Immunology
- Microbiology
- Vaccinology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant global health threat due to rising antibiotic resistance.
- The urgent need for an effective Staphylococcus aureus vaccine is underscored by treatment failures.
- Previous clinical trials for S. aureus vaccines have not yielded sustained efficacy.
Discussion:
- Antibodies targeting distinct S. aureus surface polysaccharides can independently mediate bacterial killing and protection in preclinical models.
- When combined, antibodies to two different S. aureus surface polysaccharides were found to bind and inhibit each other's activity.
- This interaction presents a novel explanation for the limited success of antibody-based immunity against S. aureus.
Key Insights:
- Specific antibodies against S. aureus surface polysaccharides are crucial for effector cell-mediated killing and protection.
- The combination of antibodies targeting different polysaccharides can lead to mutual abrogation of function.
- This finding challenges existing strategies for developing S. aureus vaccines based on surface antigens.
Outlook:
- Further research is needed to understand the mechanisms behind antibody interference.
- New vaccine strategies may need to consider the complex interactions between antibodies and multiple S. aureus surface targets.
- Developing effective Staphylococcus aureus vaccines remains a critical goal to combat antibiotic resistance.
More Related Videos
08:49Printed Glycan Array: A Sensitive Technique for the Analysis of the Repertoire of Circulating Anti-carbohydrate Antibodies in Small Animals
Published on: February 14, 2019
09:57Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
Related Concept Videos
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Humoral Immune Responses
Obedience
Cross-reactivity
Antidotes
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
Affinity and Avidity